Takeda
TAK-788
Carcinoma, Non-Small-Cell Lung
Countdown
117days
Phase 2 readout · Oct 31, 2026
What's at stake
Phase 2 trial results for TAK-788 in Carcinoma, Non-Small-Cell Lung are due Oct 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT02716116: Phase 2 trial, sponsor Takeda, drug TAK-788. Primary completion date 2026-10-31 (estimated).”